Wyeth and Elan in a World of Pain

Image via Wikipedia
A little over a month ago, I wrote a post detailing how I thought the Bapineuzumab trial (which had just released phase 2 results) was a total loser.
It was, and still is, my contention that mAbs targeting APP, Tau, gamma secretase or the protein du jour in brain soup will not be effective [...]

Bapineuzumab Fails Trial

Image via Wikipedia

For a drug expected to top $7B in annual sales, even a partial success looks like a failure to me.  I’ve talked about the efficacy in modulating APP for the treatment of Alzheimer’s a few times and Derek Lowe @ has some great articles, so if you’re not familiar, I‘d check them out [...]

Astellas Pharma and CoMentis Sign $760M Alzheimer’s Deal

Astellas Pharma, Inc. and CoMentis, Inc. announced today that the companies have entered into an agreement to develop products from CoMentis’ beta-secretase inhibitor program, including the recently initiated, phase 2, lead candidate compound CTS-21166, an oral beta-secretase inhibitor for the treatment of Alzheimer’s disease. The agreement also includes a research collaboration to develop additional beta-secretase [...]